Tralokinumab for Dupilumab Failures

Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7

NCT03761537 ·Status: COMPLETED ·Phase: PHASE3

Ophthalmological Adverse Events of Tralokinumab in AD

NCT05682976 ·Status: COMPLETED

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)

NCT03160885 ·Status: COMPLETED ·Phase: PHASE3

Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis

NCT00125333 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma

NCT04200755 ·Status: COMPLETED ·Phase: PHASE2

Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy

NCT01149759 ·Status: COMPLETED ·Phase: NA

Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation

NCT05378698 ·Status: TERMINATED ·Phase: PHASE2/PHASE3

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)

NCT03131648 ·Status: COMPLETED ·Phase: PHASE3

Study to Evaluate the Efficacy and Safety of 0.1% and 0.03% Tacrolimus Ointment Administered in Adults With Moderate to Severe Atopic Dermatitis

NCT00691145 ·Status: COMPLETED ·Phase: PHASE3

A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis

NCT05983068 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Distribution of Tacrolimus in Skin, Atopic Dermatitis

NCT00534508 ·Status: COMPLETED ·Phase: PHASE2

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

NCT03363854 ·Status: COMPLETED ·Phase: PHASE3

A Study of TAVO101 in Atopic Dermatitis Patients

NCT06176040 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function

NCT04556461 ·Status: COMPLETED ·Phase: PHASE2

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

NCT03526861 ·Status: COMPLETED ·Phase: PHASE3

Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis

NCT03389893 ·Status: TERMINATED ·Phase: PHASE4

Dupilumab Skin Barrier Function Study in Atopic Dermatitis

NCT04447417 ·Status: COMPLETED ·Phase: PHASE4

Study of 0417 Ointment in the Treatment of Atopic Dermatitis

NCT01139450 ·Status: COMPLETED ·Phase: PHASE3

A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable

NCT02755649 ·Status: COMPLETED ·Phase: PHASE3

A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)

NCT02407756 ·Status: COMPLETED ·Phase: PHASE2

A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD

NCT05470114 ·Status: COMPLETED ·Phase: PHASE2

Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

NCT03345914 ·Status: COMPLETED ·Phase: PHASE3

Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis

NCT04718870 ·Status: COMPLETED ·Phase: PHASE4

Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND

NCT03587805 ·Status: COMPLETED ·Phase: PHASE3

Phase 1a/1b Study of TRB-061 in Healthy Participants & Atopic Dermatitis Patients

NCT06934252 ·Status: RECRUITING ·Phase: PHASE1